Navigation Links
Developing Antimetastasis Therapy- An Early Stage of Tumor Control.

A new mechanistic description of how tumor cells migrate to the lymphatic system in the early stages of tumor metastasis has been developed by a swiss-based research team. This new understanding holds significant potential for developing anti-metastasis therapies.

Scientists know that tumor cells spread via the lymphatic system, but they dont understand the details of how this deadly migration takes place. In the June 2007 issue of the journal Cancer Cell, EPFL Professor Melody Swartz and postdoctoral researcher Jacqueline Shields provide an explanation along with data to support it.

Tumors produce excess fluid that continually percolates from the tumor towards nearby lymphatic vessels. The EPFL research shows how tumor cells use a clever chemical strategy to exploit this slow, one-way flow in order to migrate to functional lymphatic vessels.

As part of their intercellular drainage job, lymphatic tissues secrete small quantities of a signaling molecule. Cells migrate towards high concentrations of this molecule, so if they are close enough to the lymphatic to sense the molecule, they will migrate towards the vessel. Swartzs group showed that tumor cells secrete this same molecule. Since lymphatics drain fluid, there will always be slow fluid flow going away from the tumor into the lymphatic vessel.

This slow flow biases the concentration distribution of this molecule towards the lymphatic, and the tumor cell follows it, like the proverbial carrot on a stick. Near the vessel, concentrations of the signaling molecule are reinforced by the lymphatics own secretions, fine tuning the tumor cells migration and guaranteeing that they will home in on the lymphatic.

To demonstrate this new concept, the researchers engineered a tissue culture model of the tumor-lymphatic microenvironment and developed computational models to calculate the gradients of the signaling molecule.

The study provides the fir
'"/>




Page: 1 2

Related medicine news :

1. Risk Of Developing Arthritis
2. Developing HIV fighter
3. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
4. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
5. Men Who at Risk Of Developing Prostate Cancer
6. Identifying The Risks Of Developing Schizophrenia
7. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
8. Cancer Patients At A Greater Risk Of Developing Blood Clots
9. Young Smokers at Increased Risk Of Developing a Heart Attack
10. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
11. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
Post Your Comments:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Prototype 7 foot tall sanitizer automates disinfection of hard to clean hospital equipment 53346 1Prototype 7 foot tall sanitizer automates disinfection of hard to clean hospital equipment 53346 2National assessment done on potential invasive snail and slug pests in US 9440 1Iron isotopes as a tool in oceanography 9436 1Iron isotopes as a tool in oceanography 9436 2Iron isotopes as a tool in oceanography 9436 3